Journal article
Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma
Abstract
IMPORTANCE: The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) for moderate to severe asthma remain unclear.
OBJECTIVE: To systematically synthesize the outcomes and adverse events associated with triple therapy (ICS, LABA, and LAMA) vs dual therapy (ICS plus LABA) in children and adults with persistent uncontrolled asthma.
Authors
Kim LHY; Saleh C; Whalen-Browne A; O’Byrne PM; Chu DK
Journal
JAMA: The Journal of the American Medical Association, Vol. 325, No. 24, pp. 2466–2479
Publisher
American Medical Association (AMA)
Publication Date
June 22, 2021
DOI
10.1001/jama.2021.7872
ISSN
0098-7484